KR101086246B1 - 치환된 스피로벤즈아제핀 - Google Patents

치환된 스피로벤즈아제핀 Download PDF

Info

Publication number
KR101086246B1
KR101086246B1 KR1020057024157A KR20057024157A KR101086246B1 KR 101086246 B1 KR101086246 B1 KR 101086246B1 KR 1020057024157 A KR1020057024157 A KR 1020057024157A KR 20057024157 A KR20057024157 A KR 20057024157A KR 101086246 B1 KR101086246 B1 KR 101086246B1
Authority
KR
South Korea
Prior art keywords
chloro
spiro
aza
compound
aminobenzoyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020057024157A
Other languages
English (en)
Korean (ko)
Other versions
KR20060023157A (ko
Inventor
모나 파텔
필립 제이. 립시진스키
민 아미 지앙
Original Assignee
얀센 파마슈티카 엔.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티카 엔.브이. filed Critical 얀센 파마슈티카 엔.브이.
Publication of KR20060023157A publication Critical patent/KR20060023157A/ko
Application granted granted Critical
Publication of KR101086246B1 publication Critical patent/KR101086246B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/49—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups
    • C07C205/57—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by carboxyl groups having nitro groups and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/32—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems containing carbocyclic rings other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020057024157A 2003-06-17 2004-06-16 치환된 스피로벤즈아제핀 Expired - Fee Related KR101086246B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US47937803P 2003-06-17 2003-06-17
US60/479,378 2003-06-17
PCT/US2004/019460 WO2005037795A2 (en) 2003-06-17 2004-06-16 Substituted spirobenzazepines

Publications (2)

Publication Number Publication Date
KR20060023157A KR20060023157A (ko) 2006-03-13
KR101086246B1 true KR101086246B1 (ko) 2011-11-23

Family

ID=34465052

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020057024157A Expired - Fee Related KR101086246B1 (ko) 2003-06-17 2004-06-16 치환된 스피로벤즈아제핀

Country Status (30)

Country Link
US (2) US20040266752A1 (enExample)
EP (1) EP1633719B1 (enExample)
JP (1) JP5252614B2 (enExample)
KR (1) KR101086246B1 (enExample)
CN (1) CN100467454C (enExample)
AR (1) AR044782A1 (enExample)
AT (1) ATE444953T1 (enExample)
AU (1) AU2004281257C1 (enExample)
BR (1) BRPI0411598A (enExample)
CA (1) CA2529649C (enExample)
CL (1) CL2004001507A1 (enExample)
CR (1) CR8168A (enExample)
CY (1) CY1109585T1 (enExample)
DE (1) DE602004023501D1 (enExample)
DK (1) DK1633719T3 (enExample)
EA (1) EA011089B1 (enExample)
ES (1) ES2332724T3 (enExample)
HR (2) HRP20051006A2 (enExample)
IL (1) IL172630A (enExample)
ME (1) ME00320B (enExample)
NO (1) NO20060247L (enExample)
NZ (1) NZ544180A (enExample)
PL (1) PL1633719T3 (enExample)
PT (1) PT1633719E (enExample)
RS (1) RS20050930A (enExample)
SI (1) SI1633719T1 (enExample)
TW (1) TWI354555B (enExample)
UA (1) UA82236C2 (enExample)
WO (1) WO2005037795A2 (enExample)
ZA (1) ZA200600430B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007516177A (ja) * 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法
EP1984342A2 (en) * 2006-01-20 2008-10-29 Janssen Pharmaceutica, N.V. Novel solid forms of (4r)-1-[4-(2-chloro-5-fluorobenzoyl)amino-3-methoxybenzoyl]-1,2,3,5-tetrahydro-spiro[4h-1-benzazepine-4,1'-[2]cyclopentene]-3'-carboxylic acid
JP2010504352A (ja) * 2006-09-22 2010-02-12 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ バソプレッシン拮抗薬としてのスピロベンズアゼピン類
ATE532786T1 (de) * 2006-09-22 2011-11-15 Janssen Pharmaceutica Nv Spirobenzazepine als vasopressinantagonisten
AR066834A1 (es) * 2007-06-06 2009-09-16 Janssen Pharmaceutica Nv Espirobenzoazepanos como antagonistas de vasopresina, composiciones farmaceuticas que los contienen, proceso de preparacion y usos para el tratamiento de afecciones cardiacas, renales y del sistema nervioso central.
WO2009061786A2 (en) * 2007-11-07 2009-05-14 Janssen Pharmaceutica N.V. Combination therapy comprising angiotensin converting enzyme inhibitors and vasopressin receptor antagonists
WO2014062888A1 (en) 2012-10-18 2014-04-24 University Of South Florida Compositions and methods for treating stroke
RU2642783C2 (ru) 2012-12-26 2018-01-26 Санва Кагаку Кенкюсо Ко., Лтд. Новое производное бензоазепина и его медицинское применение
US20240190884A1 (en) * 2021-03-05 2024-06-13 Shanghai Jemincare Pharmaceutical Co., Ltd New-type benzazepine fused ring derivative

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002531A1 (en) 2000-07-05 2002-01-10 Ortho-Mcneil Pharmaceutical, Inc. Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4617302A (en) * 1984-10-15 1986-10-14 Eli Lilly And Company Inotropic agents
US5258510A (en) * 1989-10-20 1993-11-02 Otsuka Pharma Co Ltd Benzoheterocyclic compounds
DE69026708T2 (de) 1989-10-20 1997-04-03 Otsuka Pharma Co Ltd Benzoheterozyklische verbindungen
US5985869A (en) * 1989-10-20 1999-11-16 Otsuka Pharmaceutical Company, Limited Benzoheterocyclic compounds
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5849780A (en) * 1992-01-30 1998-12-15 Sanofi 1-benzenesulfonyl-1-1,3-dihydroindol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US5663431A (en) * 1992-01-30 1997-09-02 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
FR2708605A1 (fr) * 1993-07-30 1995-02-10 Sanofi Sa Dérivés du N-sulfonylindol-2-one, leur préparation, les compositions pharmaceutiques en contenant.
EP0663827A4 (en) * 1992-10-07 1995-11-15 Merck & Co Inc TOKOLYTIC OXYTOCINE RECEPTOR ANTAGONISTS.
US5512563A (en) * 1993-07-29 1996-04-30 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5464788A (en) * 1994-03-24 1995-11-07 Merck & Co., Inc. Tocolytic oxytocin receptor antagonists
ES2143049T3 (es) * 1994-04-22 2000-05-01 Pentech Pharmaceuticals Inc Formas sublinguales de dosificacion que contienen apomorfina y su uso para el tratamiento de la disfuncion erectil.
US5753648A (en) * 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
JP3282494B2 (ja) * 1995-05-16 2002-05-13 富士ゼロックス株式会社 画像定着装置
US5753715A (en) * 1995-06-02 1998-05-19 Ortho Pharmaceutical Corporation 2-disubstituted cyclohexenyl and cyclohexyl antimicrobial agents
US5726723A (en) * 1996-01-31 1998-03-10 Technology Research International Corporation Sub-twisted nematic liquid crystal display
AUPP150098A0 (en) 1998-01-27 1998-02-19 Fujisawa Pharmaceutical Co., Ltd. Benzamide derivatives
JP2007516177A (ja) * 2003-06-17 2007-06-21 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 非ペプチド置換スピロベンゾアゼピン誘導体の製造方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002002531A1 (en) 2000-07-05 2002-01-10 Ortho-Mcneil Pharmaceutical, Inc. Nonpeptide substituted spirobenzoazepines as vasopressin antagonists

Also Published As

Publication number Publication date
AR044782A1 (es) 2005-10-05
AU2004281257C1 (en) 2010-07-01
MEP49108A (en) 2011-02-10
EP1633719A2 (en) 2006-03-15
SI1633719T1 (sl) 2010-01-29
CR8168A (es) 2008-09-10
CN100467454C (zh) 2009-03-11
CL2004001507A1 (es) 2005-05-27
EA011089B1 (ru) 2008-12-30
KR20060023157A (ko) 2006-03-13
HRP20090606T1 (hr) 2010-01-31
CA2529649A1 (en) 2005-04-28
PL1633719T3 (pl) 2010-03-31
IL172630A0 (en) 2006-04-10
BRPI0411598A (pt) 2006-08-29
DK1633719T3 (da) 2010-01-04
US20040266752A1 (en) 2004-12-30
ATE444953T1 (de) 2009-10-15
US20070179128A1 (en) 2007-08-02
AU2004281257A1 (en) 2005-04-28
WO2005037795A3 (en) 2005-07-28
HRP20051006A2 (en) 2006-05-31
JP2007521272A (ja) 2007-08-02
RS20050930A (sr) 2008-04-04
CA2529649C (en) 2012-01-31
ES2332724T3 (es) 2010-02-11
NO20060247L (no) 2006-03-13
DE602004023501D1 (de) 2009-11-19
EP1633719B1 (en) 2009-10-07
JP5252614B2 (ja) 2013-07-31
CY1109585T1 (el) 2014-08-13
ZA200600430B (en) 2009-08-26
US7687494B2 (en) 2010-03-30
PT1633719E (pt) 2009-11-11
ME00320B (me) 2011-05-10
AU2004281257B2 (en) 2010-02-04
WO2005037795A2 (en) 2005-04-28
IL172630A (en) 2011-10-31
EA200501831A1 (ru) 2006-06-30
CN1835925A (zh) 2006-09-20
UA82236C2 (en) 2008-03-25
NZ544180A (en) 2009-01-31
TWI354555B (en) 2011-12-21
TW200515911A (en) 2005-05-16

Similar Documents

Publication Publication Date Title
AU716122B2 (en) Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders
US7687494B2 (en) Substituted spirobenzazepines
US7825111B2 (en) Substituted spiroheterocycles
JP2002513385A (ja) カリウムチャンネル阻害剤
JP4571863B2 (ja) 抗痛覚過敏剤として有用なキナゾリノン誘導体
TW200821286A (en) 2-phenyl-indoles as prostaglandin D2 receptor antagonists
SK148898A3 (en) Aryl substituted cyclic amines as selective dopamine d3 ligands
JP2000516619A (ja) Ｉｌ―８レセプターアンタゴニスト
AU723349B2 (en) Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
JP2010504351A (ja) バソプレッシン拮抗薬として使用されるスピロベンズアゼピン類
TW200812976A (en) Compounds which inhibit the glycine transporter and uses thereof
MXPA06002065A (es) Derivados de bencimidazolona y quinazolinona sustituidos con biciclo-3.1.1-heptano como agonistas en receptores orl1 humanos.
ES2247107T3 (es) Nuevos indanilimidazoles policiclicos con actividad adrenergica.
EP0585116B1 (en) 1-Alkoxy-naphthalene-2-carboxamide derivatives with high affinity for the serotonin 5-HT1A receptor
MXPA05014057A (en) Substituted spirobenzazepines
CN100551915C (zh) 8-氯-2,3-苯二氮䓬衍生物
EP1615896A1 (en) Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds
JP2003501471A (ja) Ｉｌ−８受容体アンタゴニスト
KR20060134927A (ko) 사람 ｏｒｌ1 수용체에 대한 효능제로서의바이사이클로[3.1.1]헵탄 치환된 벤즈이미다졸론 및퀴나졸리논 유도체

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

FPAY Annual fee payment

Payment date: 20141022

Year of fee payment: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 20151016

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

FPAY Annual fee payment

Payment date: 20161019

Year of fee payment: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

FPAY Annual fee payment

Payment date: 20171018

Year of fee payment: 7

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

FPAY Annual fee payment

Payment date: 20181018

Year of fee payment: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 10

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20211118

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20211118

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000